AR040036A1 - Tratamiento de la mucositis - Google Patents

Tratamiento de la mucositis

Info

Publication number
AR040036A1
AR040036A1 ARP030101748A ARP030101748A AR040036A1 AR 040036 A1 AR040036 A1 AR 040036A1 AR P030101748 A ARP030101748 A AR P030101748A AR P030101748 A ARP030101748 A AR P030101748A AR 040036 A1 AR040036 A1 AR 040036A1
Authority
AR
Argentina
Prior art keywords
mucositis
methods
compositions
nucleoside
ribose
Prior art date
Application number
ARP030101748A
Other languages
English (en)
Inventor
Robert A Shalwitz
James L Leach
Paul W Johns
Tapas Das
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR040036A1 publication Critical patent/AR040036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Composiciones y métodos para aliviar mucositis, donde dichos métodos y composiciones se refieren a la formulación o uso de determinados derivados de nucleósidos, en especial ADP-ribosa, que son de la fórmula general A-B-X y sales aceptables para uso farmacéutico de los mismos, donde "A" es una estructura nucleosídica seleccionada entre adenosina, guanosina y uridina; "B" es un enlace difosfato unido al carbono 5' de la porción ribosa del nucleósido; y "X" está unido a B que es una porción seleccionada entre hidrógeno, furanosa o piranosa. También se describen realizaciones de productos farmacéuticos y nutricionales líquidos de los mismos, incluyendo tabletas, enjuagues bucales u otras formas de productos que permitan recubrir eficazmente las áreas de mucosa oral, laríngea u otras áreas de mucosa. Se ha encontrado que estas composiciones y métodos alivian eficazmente la mucositis en individuos susceptibles, en especial cuando se administran antes, durante o después de los tratamientos asociados comúnmente con el desarrollo de mucositis, tal como determinadas quimioterapias, terapias de radiación o combinaciones de los mismos.
ARP030101748A 2002-05-21 2003-05-20 Tratamiento de la mucositis AR040036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38222502P 2002-05-21 2002-05-21

Publications (1)

Publication Number Publication Date
AR040036A1 true AR040036A1 (es) 2005-03-09

Family

ID=29584378

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101748A AR040036A1 (es) 2002-05-21 2003-05-20 Tratamiento de la mucositis

Country Status (9)

Country Link
US (3) US20030236217A1 (es)
EP (1) EP1509234B1 (es)
AR (1) AR040036A1 (es)
AT (1) ATE417616T1 (es)
AU (1) AU2003230952A1 (es)
DE (1) DE60325353D1 (es)
HK (1) HK1074784A1 (es)
TW (1) TW200402301A (es)
WO (1) WO2003099297A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040989A1 (it) * 2004-05-18 2004-08-18 Gentium Spa Uso del sulglicotide per iul trattamento delle mucositi
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
GB0501476D0 (en) * 2005-01-25 2005-03-02 Heptagen Ltd Treatment for mucositis
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
US20070231274A1 (en) * 2006-03-28 2007-10-04 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
WO2009043134A1 (en) 2007-10-03 2009-04-09 Myrex Pharmaceuticals Inc. Mouthwash and method of using same for the treatment of mucositis or stomatitis
AR058834A1 (es) * 2006-11-06 2008-02-27 Univ Nac Quilmes Un compuesto con actividad inhibitoria de una proteina celular rho-gtpasa, un procedimiento para su obtencion, composiciones farmaceuticas que lo comprenden y un metodo para el tratamiento de una indicacion mediada por una proteina celular rho-gtpasa
US20100305071A1 (en) * 2007-08-30 2010-12-02 Prelief Inc. Methods for improving healing of an oral lesion using a glycerophosphate salt
JP5504179B2 (ja) * 2008-03-03 2014-05-28 トスク インコーポレーティッド 毒性を低減するためのメトトレキセートアジュバントおよびその使用法
EP2418945B1 (en) * 2009-04-15 2018-12-05 BMG PHARMA S.p.A. Mineral salt-sulfonic acid compositions and methods of use
WO2013089131A1 (ja) * 2011-12-16 2013-06-20 株式会社林原 歯周病の予防及び／又は治療のための口腔内洗浄用組成物
US11103546B2 (en) 2014-01-29 2021-08-31 Vita Ice Therapeutics Llc Edible oil compositions to treat oral complications and methods of using same
LT3416654T (lt) * 2016-02-18 2022-01-10 Invirsa, Inc. 5’-adenozindifosfato ribozės (adpr) medicininis panaudojimas
US10946034B2 (en) 2018-03-27 2021-03-16 Invirsa, Inc. Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
KR20210075968A (ko) * 2018-10-17 2021-06-23 레이크우드 아메덱스, 인크. 구강 점막염을 치료하기 위한 방법 및 조성물
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
KR20230036274A (ko) 2021-09-07 2023-03-14 정근영 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118672A (en) * 1976-07-28 1978-10-03 Nippon Electric Company, Ltd. Attenuation equalizer having constant resistance
US5118672A (en) * 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
JPH07247210A (ja) * 1994-03-09 1995-09-26 Sunstar Inc 口腔用組成物
US5656284A (en) * 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
US5942243A (en) * 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
JP2001515916A (ja) * 1997-09-11 2001-09-25 オクシジェン，インコーポレイテッド 悪性および伝染性疾患の治療用にニコチンアミド・アデニン・ジヌクレオチドならびにその類似物を用いる治療法
US6197334B1 (en) * 1998-04-13 2001-03-06 Donald V. Renda Lozenge and method of making
US6624150B2 (en) * 1999-02-26 2003-09-23 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7056894B2 (en) * 2001-01-04 2006-06-06 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof

Also Published As

Publication number Publication date
WO2003099297A1 (en) 2003-12-04
ATE417616T1 (de) 2009-01-15
EP1509234A1 (en) 2005-03-02
DE60325353D1 (de) 2009-01-29
EP1509234B1 (en) 2008-12-17
US20030236217A1 (en) 2003-12-25
AU2003230952A1 (en) 2003-12-12
US20060105985A1 (en) 2006-05-18
HK1074784A1 (en) 2005-11-25
US20080081796A1 (en) 2008-04-03
TW200402301A (en) 2004-02-16

Similar Documents

Publication Publication Date Title
AR040036A1 (es) Tratamiento de la mucositis
GT199900203A (es) Composiciones de celecoxib.
BRPI0412489A (pt) composição de confeito mastigável liberando para as superfìcies dentárias uma dose unitária de uma enzima
AR035642A1 (es) Uso de una composicion de celecoxib para el alivio rapido del dolor
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
GT200000005A (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer.
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
AR037407A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii
AR052057A1 (es) Composiciones orales que contienen extractos de rosmarinus y metodos ralacionados
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
EA000626B3 (ru) Синергические комбинации зидовудина, 1592u89 и зтс или ftc
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
PA8581801A1 (es) Formulaciones que contienen un compuesto de indolinona
GT199100051A (es) Composiciones farmaceuticas y metodos para aliviar sintomas de dolores gastrointestinales inducidos por drogas antiinflamatorias no esteroidales
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
BR9909872A (pt) uso de dexmedetomidina para uma unidade de sedação de proteção intensiva
GT200600397A (es) Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales
AR025046A1 (es) Inhibidores il-5 no esteroidales, procedimientos e intermediarios para su preparacion y composiciones farmaceuticas que comprenden dichos inhibidores
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
ES2526359T3 (es) Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos
PA8590801A1 (es) Derivados de nucleosido antivirales
GT199900083A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica.
BR0206087A (pt) Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias

Legal Events

Date Code Title Description
FB Suspension of granting procedure